Wolfgang Miesbach: Factor VIII Aurora Redefines the Biology of Coagulation
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Johnathan J. Morris et al, published in American Society of Hematology, adding:
“Haemophilia A is defined by too little factor VIII.
So what happens when FVIII works too well?
Factor VIII Aurora (FVIII-R571S) — newly characterised in Blood by Lindsey George and colleagues at CHOP — is the first naturally occurring gain-of-function FVIII variant. It was identified in a patient with recurrent thrombosis and early death (NEJM 2025), and the mechanism turns out to be strikingly simple:
A single amino acid change raises the affinity of activated FVIII for FIXa by 10–20-fold. That one property accounts for the entire phenotype:
- 6-fold higher one-stage activity, yet normal chromogenic activity — the CSA uses FIXa in excess and is blind to the difference
- ‘APC resistance’ that isn’t intrinsic: the variant is cleaved by APC normally, but tighter FIXa binding shields it
- reduced A2-domain dissociation
- 4–5-fold greater haemostatic potency and a clearly prothrombotic phenotype in mice
The gene therapy parallel is hard to miss. Just as FIX-Padua (R338L) reshaped haemophilia B gene therapy, an enhanced-potency FVIII could do the same for haemophilia A — but FVIII carries a higher VTE risk than FIX, and Aurora is a sharp reminder of how narrow the safe expression window may be.”
Title: Factor VIII Aurora: A Naturally Occurring Gain of Function FVIII Variant with Enhanced FIXa Affinity
Authors: Johnathan J. Morris, Robert J Davidson, Connor T. Watson, Lindsey A. George
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Sep 20, 2026, 16:42Kate Grushetzkaya: The Essential Flow Cytometry Checklist – 6 Steps to Better Data
-
Sep 20, 2026, 16:32New Episode of The Hematologist Podcast – ASH
-
Sep 20, 2026, 16:26Thomas Schinecker: A New Era for Health Innovation – Inside the Roche Genentech Innovation Center
-
Sep 20, 2026, 16:19Astha Srivastava: The Missing Megakaryocytes in Amegakaryocytic Thrombocytopenia
-
Sep 20, 2026, 16:19Heghine Khachatryan: An Elegant Example of Precision Thrombolysis – Targeting the Scaffold of Microvascular Thrombosis
-
Sep 20, 2026, 16:01Mohamed Ismail: Managing Extensive Iliofemoral and Inferior Vena Cava DVT
-
Sep 20, 2026, 15:58Can αIIbβ3 Receptor Play a Role in Platelet Production – Glanzmann’s Research Foundation
-
Sep 20, 2026, 15:46Alexsander Santiago: Evaluating Clinical Harm from Missing versus Overdiagnosing HIT
-
Sep 20, 2026, 15:28Nico Gagelmann: iMTSS to Dissect the Drivers of Post-Transplant Outcomes